Professor George Fu Gao obtained his PhD degree from Oxford University, UK and did his postdoc work in both Oxford University and Harvard University (with a brief stay in Calgary University). He is the former director general of the Chinese Center for Disease Control and Prevention, and the former vice-president of the National Natural Science Foundation of China. Currently, he is working as a professor at the Institute of Microbiology, Chinese Academy of Sciences.
 

Professor Gao has been a key leader in the public health field, making remarkable contributions to research and discovery through basic research, clinical evaluation, and advocacy. He has made many remarkable contributions to the scientific field of control and prevention of emerging infectious diseases. His contribution in science is not only for basic life/medical sciences but also for clinical-related preventive medical sciences and public health, which can be reflected from his publications in the top scientific journals, i.e., Nature, Science, Cell, The Lancet and The New England Journal of Medicine. During the COVID-19 outbreak, he has co-discovered the pathogen SARS-CoV-2, and pioneered the development of the first approved neutralizing antibody drug (Ely Lilly Etesevimab) and the first approved recombinant protein subunit vaccine for COVID-19 in the world.
 

He is a member (academician) of Chinese Academy of Sciences (CAS), an international member of the U.S. National Academy of Sciences (NAS), a foreign member of the U.K. Royal Society (RS), a member of the German National Academy of Sciences Leopoldina, a fellow of African Academy of Sciences and a fellow of The World Academy of Sciences (TWAS). He has received the TWAS Basic Medical Sciences Award and Lecture Award, Nikkei Asia Prize in Japan and The Gamaleya Medal in Russia. He is the founding editor-in-chief of both China CDC Weekly and hLife journals.

Education and Appointment

1. Vice President, National Natural Science Foundation of China (NSFC) (In charge of both Biology and Medicine dept) (2018 – 2022)
2. Director-General, Chinese Center for Disease Control and Prevention (China CDC) (2017 – 2022)
3. Dean Savaid Medical School, University of Chinese Academy of Sciences (2015 - present)
4. Deputy Director-General, Chinese Center for Disease Control and Prevention (2011 – present)
5. Vice-President, Beijing Institutes of Life Science, Chinese Academy of Sciences (CAS) (2008 - present)
6. Professor, Institute of Microbiology, Chinese Academy of Sciences (2008 - present)
7. Director, CAS Key Laboratory of Pathogenic Microbiology and Immunology, IMCAS (2008 - present)
8. Professor, Director-General, Institute of Microbiology, Chinese Academy of Sciences (IMCAS) (2004 – 2008)
9. Research Lecturer, Nuffield Dept. of Clinical Medicine, Oxford University (2001 – 2006)
10. Welcome Trust (UK) International Research Fellow, Howard Hughes Medical Institute, Children's Hospital; Dept. of Biological Chemistry and Molecular Pharmacology, Harvard Medical School; and Dept. of Molecular and Cellular Biology, Harvard University (Drs Don C Wiley and Stephen C Harrison lab) (1999 – 2001)
11. Research Associate (Band 3), MRC Human Immunology Unit, Institute of Molecular Medicine, University of Oxford (1998-1999)
12. Welcome Trust/MRC Postdoctoral Research Assistant (RS1A), Nuffield Dept. of Clinical Medicine, Institute of Molecular Medicine, Oxford University, Drs John Bell, Andrew McMichael and Bent Jakobsen lab. (Three months of academic visit as a postdoc fellow at Dept. of Clinical Neurosciences, Dr Robert Bell lab, The University of Calgary, Canada, in the end of 1994, before taking up the Oxford postdoc position) (1995 – 1998)
13. Teaching Assistant and Lecturer (Virology), College of Vet. Med., Beijing Agricultural University (BAU), P.R. China (1987 – 1991)
14. Oxford University, United Kingdom, DPhil (1991- 1994)
15. Beijing Agricultural University, China M.Sc (1983 – 1986)
16. Shanxi Agricultural University, China B.Sc, DVM (1979 – 1983)

Awards and Honors

1. TWAS Medal Lectures (2022)
2. Honorary Doctorate (PhD) of City University of Macau (2022)
3. Scientific and Technological Award-Chinese Medical Association (2011, 2022)
4. The Qiu Shi Outstanding Scientist and Outstanding Scientific Research Team Awards (2019)
5. HKU Centennial Distinguished Chinese Scholar (2019)
6. The Gamaleya Medal (Russia 2018)
7. The 3rd Shulan Medical Sciences Award (2016)
8. The 16th Wu Jieping-Paul Janssen Medical & Pharmaceutical Awards (2015)
9. Japanese Foreign Minister’s Award (2015)
10. HLHL Foundation for Scientific and Technological Advancement (2015)
11. National Prize for Progress in Science and Technology, P. R. China (2011 and 2014)
12. Outstanding Science and Technology Achievement Prize of the Chinese Academy of Sciences (2014)
13. Tan Jiazhen (C. C. Tan) Grand Achievement Prize (2014) and Life Science Innovation Award (2008)
14. (Japan) Nikkei Asia Prize (2014)
15. Science and Technology Innovation Talent-CCTV Grand Ceremony for Science and Technology (2013) (Top 10 Scientists in 2013)
16. SEBM Distinguished Scientist Award (Society for Experimental Biology and Medicine, USA) (2013)
17. TWAS (The Third World Academy of Sciences) Prize (Medical Sciences) (2012)
18. Beijing Scientific and Technological Award (2011)
19. Scientific and Technological Award-Chinese Preventive Medicine Association (2011, 2017)
20. Scientific and Technological Award-Chinese Medical Association (2011)
21. Thompson Reuters Research Front Award (2008)
22. New century candidate of the national project “Hundred-Thousand-Talents” (Awarded by Ministry of Personnel of the People’s Republic of China) (2006)
23. National Natural Science Foundation of China (NSFC) “Distinguished Young Investigator” (2005)
24. Chinese Academy of Sciences (CAS) “Hundred-Talent Project” (2004)
25. Young Scientist Award-China Association for Science and Technology (1988)

Professional Titles and Membership

1. Fellow, Chinese Academy of Medical Sciences
2. Fellow, China Academy of Chinese Medical Sciences
3. Member, Academia Europaea
4. Member, The German National Academy of Sciences Leopoldina
5. International Member, National Academy of Sciences (NAS, USA)
6. Member, National Academy of Medicine (NAM, USA)
7. Corresponding Member, Brazilian Academy of Sciences (BAS)
8. Member (academician), International Eurasian Academy of Sciences (IEAS)
9. Fellow, The Royal Society of Edinburgh (RSE)
10. Fellow, African Academy of Sciences (AAS)
11. Associate Member, European Molecular Biology Organization (EMBO)
12. Fellow, American Association for the Advancement of Science (AAAS)
13. Fellow, American Academy of Microbiology (AAM)
14. Fellow, The Third World Academy of Sciences (TWAS, Also called The World Academy of Sciences)
15. Member (academician), Chinese Academy of Sciences (CAS)
16. Vice Chair of Division of Virology, International Union of Microbiological Societies (IUMS)
17. Immediate Past-President of Asian Federation of Biotechnology (AFOB)
18. President of Chinese Society of Biotechnology
19. Immediate Past-President of Chinese Society for Virology
20. Vice President of Chinese Medical Association
21. Steering Committee Member, International Consortium of Antivirals
22. Honorary Professor, Hong Kong University
23. Visiting Professor, Oxford University    
24. Editorial Board: Cell, EMBO Journal, Journal of General Virology (UK-SGM), Experimental Biology and Medicine, Vector-borne and Zoonotic Diseases, Zoonoses and Public Health, Philosophical Transactions of the Royal Society B: Biological Sciences, Antiviral Research, Protein and Cell (Deputy Editor-in-Chief), Emerging Microbes and Infections, Chinese Science Bulletin (in Chinese, Editor-in-Chief), Chinese Journal of Biotechnology (in Chinese), China CDC Weekly (Editor-in-Chief), Journal of Microbes and Infection etc.

Research

Gao’s contribution to science is not only for basic life/medical sciences but also for clinical-related preventive medical sciences and public health, which can be reflected from his “grand-slam” publications in 5 top-niche scientific journals, i.e., Nature, Science, Cell, The Lancet and The New England Journal of Medicine.
 

Gao is a leading scientist in the field of pathogenic microorganisms and immunology in China and worldwide, and he has long been engaged in the transmission of pathogenic microorganisms across hosts, infection mechanisms and hosts cellular immunity, as well as public health policy and global health strategy, including Influenza, MERS, Ebola, Zika, Chikungunya, and especially for COVID-19 pandemic’s prevention and control in China. At the time of the outbreak of severe pneumonia by COVID-19, Gao has made outstanding contributions, including the design of drugs and vaccines based on the interaction between viral envelope spike proteins and the host. 
 

At the time of the outbreak of COVID-19, Gao led the Chinese Center for Disease Control and Prevention (China CDC) team to be the first to isolate the new coronavirus, to sequence the entire genome as well as establishing the main epidemiological parameters (such as transmission route, incubation period, etc.). He led the coordination of several countries across scientific research panels and quickly issued alarms to the world, sharing scientific data with peers in the world by using top- niche magazine platforms such as The New England Journal of Medicine and The Lancet, also share China’s data in prevention and protection of public health with the world, and contributing Chinese wisdom to the world’s epidemic prevention and control. In terms of vaccine and drug research and development: the virus isolated by the China CDC provided the virus seed and BSL-3 conditions to producing the new coronavirus inactivated vaccines for both Sinopharm and SinoVac, and the new coronavirus recombinant protein vaccine ZF2001 developed by the Gao’s team is already in use in China, and was approved for the Emergency Use Authorization (EUA) in Uzbekistan and Republic of Indonesia. In addition, the new coronavirus monoclonal antibody developed (Etesevimab for Eli Lilly) was approved by FDA of United States and the European Medicines Agency for EUA in collaboration with Eli Lilly and Junshi. The successful control of COVID-19 pandemic in China, from initial containment to recent suppression, showed Gao’s strong leadership and coordination work as DG of China CDC.    

Publications

(Over 900 peer-reviewed scientific publications, with an H-index of 137, till August-2024))

1. Liu*, W. J., Liu, P., Lei, W., Jia, Z., He, X., Shi, W., Tan, Y., Zou, S., Wong, G., Wang, J., Wang, F., Wang, G., Qin, K., Gao, R., Zhang, J., Li, M., Xiao, W., Guo, Y., Xu, Z., Zhao, Y., Song, J., Zhang, J., Zhen, W., Zhou, W., Ye, B., Song, J., Yang, M., Zhou, W., Dai, Y., Lu, G., Bi, Y., Tan, W., Han, J., Gao*, G. F. and Wu*, G., 2024, Surveillance of SARS-CoV-2 at the Huanan seafood market. Nature, 631 (8020): 402–408.
2. Sun, H., Li, H., Tong, Q., Han, Q., Liu, J., Yu, H., Song, H., Qi, J., Li, J., Yang, J., Lan, R., Deng, G., Chang, H., Qu, Y., Pu, J., Sun, Y., Lan, Y., Wang, D., Shi, Y., Liu, W. J., Chang, K. C., Gao*, G. F. and Liu*, J., 2023, Airborne transmission of human-isolated avian H3N8 influenza virus between ferrets. Cell, 186 (19): 4074-4084.e11.
3. Peng, Q., Xie, Y., Kuai, L., Wang, H., Qi, J., Gao*, G. F. and Shi*, Y., 2023, Structure of monkeypox virus DNA polymerase holoenzyme. Science, 379 (6627): 100-105.
4. Peng, Q., Yuan, B., Cheng, J., Wang, M., Gao, S., Bai, S., Zhao, X., Qi*, J., Gao*, G. F. and Shi*, Y., 2023, Molecular mechanism of de novo replication by the Ebola virus polymerase. Nature, 622 (7983): 603-610.
5. Pan, Y., Wang, L., Feng, Z., Xu, H., Li, F., Shen, Y., Zhang, D., Liu, W. J., Gao*, G. F. and Wang*, Q., 2023, Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis. The Lancet, 401(10377):664-672.
6. Dai, L., Duan, H., Liu, X., Zhou, H., Duan, M., An, Y., Yuan, L., Zhao, X., Xu, K., Wu, Q. and Gao*, G. F., 2023, Omicron neutralisation: RBD-dimer booster versus BF.7 and BA.5.2 breakthrough infection. The Lancet, 402 (10403): 687-689.
7. Han, P., Li, L., Liu, S., Wang, Q., Zhang, D., Xu, Z., Han, P., Li, X., Peng, Q., Su, C., Huang, B., Li, D., Zhang, R., Tian, M., Fu, L., Gao, Y., Zhao, X., Liu, K., Qi*, J., Gao*, G. F. and Wang*, P., 2022, Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2. Cell, 185 (4): 630-640.e10.
8. Li, L., Liao, H., Meng, Y., Li, W., Han, P., Liu, K., Wang, Q., Li, D., Zhang, Y., Wang, L., Fan, Z., Zhang, Y., Wang, Q., Zhao*, X., Sun*, Y., Huang*, N., Qi*, J. and Gao*, G. F., 2022, Structural basis of human ACE2 higher binding affinity to currently circulating Omicron SARS-CoV-2 sub-variants BA.2 and BA.1.1. Cell, 185 (16): 2952-2960.e10.
9. Zhao, X., Li, D., Ruan, W., Chen, Z., Zhang, R., Zheng, A., Qiao, S., Zheng, X., Zhao, Y., Dai, L., Han, P. and Gao*, G. F., 2022, Effects of a prolonged booster interval on neutralization of Omicron variant. The New England Journal of Medicine, 386 (9): 894-896.
10. Dai, L., Gao, L., Tao, L., Hadinegoro, S.R., Erkin, M., Ying, Z., He, P., Girsang, R.T., Vergara, H., Akram, J., Satari, H.I., Khaliq, T., Sughra, U., Celi, A.P., Li, F., Li, Y., Jiang, Z., Dalimova, D., Tuychiev, J., Turdikulova, S., Ikram, A., Lastra, N.F., Ding, F., Suhardono, M., Fadlyana, E., Yan, J., Hu, Z., Li, C., Abdurakhmonov, I.Y. and Gao*, G. F., 2022, Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults. The New England Journal of Medicine,  386(22):2097-2111.
11. Liu, K., Pan, X., Li, L., Yu, F., Zheng, A., Du, P., Han, P., Meng, Y., Zhang, Y., Wu, L., Chen, Q., Song, C., Jia, Y., Niu, S., Lu, D., Qiao, C., Chen, Z., Ma, D., Ma, X., Tan, S., Zhao, X., Qi*, J., Gao*, G. F. and Wang*, Q., 2021, Binding and molecular basis of the bat coronavirus RaTG13 virus to ACE2 in humans and other species. Cell, 184 (13): 3438-3451.e10.
12. Li, J., Lai, S., Gao, G. F. and Shi, W., 2021, The emergence, genomic diversity and global spread of SARS-CoV-2. Nature, 600 (7889): 408-418.
13. Modhiran, N., Song, H., Liu, L., Bletchly, C., Brillault, L., Amarilla, A. A., Xu, X., Qi, J., Chai, Y., Cheung, S. T. M., Traves, R., Setoh, Y., Bibby, S., Scott, C. A. P., Freney, M. E., Newton, N. D., Khromykh, A. A., Chappell, K. J., Muller, D. A., Stacey, K. J., Landsberg, M. J., Shi, Y, Gao*, G. F., Young*, R. and Watterson*, D., 2021, A broadly protective antibody that targets the flavivirus NS1 protein. Science, 371 (6525): 190-194.
14. Dai, L., Zheng, T., Xu, K., Han, Y., Xu, L., Huang, E., An, Y., Cheng, Y., Li, S., Liu, M., Yang, M., Li, Y., Chen, H., Yuan, Y., Zhang, W., Ke, C., Wong, G., Qi, J., Qin*, C., Yan*, J. and Gao*, G. F., 2020, A universal design of betacoronavirus vaccines against COVID-19, MERS and SARS. Cell, 182 (3): 722-733.
15. Wu*, Y., Wang, F., Shen, C., Peng, W., Li, D., Zhao, C., Li, Z., Li, S., Bi, Y., Yang, Y., Gong, Y., Xiao, H., Fan, Z., Tan, S., Wu, G., Tan, W., Lu, X., Fan, C., Wang, Q., Liu, Y., Zhang, C., Qi, J., Gao*, G. F., Gao*, F. and Liu*, L., 2020, A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science, 368 (6496): 1274-1278.
16. Wang, H., Zhang, Y., Huang, B., Deng, W., Quan, Y., Wang, W., Xu, W., Zhao, Y., Li, N., Zhang, J., Liang, H., Bao, L., Xu, Y., Ding, L., Zhou, W., Gao, H., Liu, J., Niu, P., Zhao, L., Zhen, W., Fu, H., Yu, S., Zhang, Z., Xu, G., Li*, C., Lou*, Z., Xu*, M., Qin*, C., Wu*, G., Gao*, G. F., Tan*, W. and Yang*, X., 2020, Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell, 182 (3): 713–721.
17. Li, Z., Song, T., Qi, X., Zhou, L., Li, Y., Sun, X., Wu, D., An, Z., Ren, X., Peng, Z., Chen, W., Zhang, M., Yang, X., Wang, Q., Cui, J., Zhang, T., Qin, Y., Ni, D., Yin, W., Zhang, R., Yu, H., Xia, Y., Rodewald, L., Feng, L., Chen, Q., Gao*, G. F. and Feng*, Z., 2020, Active case finding with case management is key to tackling the COVID-19 pandemic. The Lancet, 396 (10243): 63-70.
18. Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., Niu, P., Zhan, F., Ma, X., Wang, D., Xu, W., Wu*, G., Gao*, G. F., Tan*, W and China Novel Coronavirus Investigating and Research Team, 2020, A Novel Coronavirus from Patients with Pneumonia in China, 2019. The New England Journal of Medicine, 382 (8):727-733.
19. Song, H., Zhao, Z., Chai, Y., Jin, X., Li, C., Yuan, F., Liu, S., Gao, Z., Wang, H., Song, J., Vazquez, V., Zhang, Y., Tan, S., Morel, C. M., Yan, J., Shi, Y., Qi, J., Gao*, F. and Gao*, G. F., 2019, Molecular basis of arthritogenic alphavirus receptor MXRA8 binding to Chikungunya virus envelope protein. Cell, 177 (7): 1714-1724.
20. Zhao, X., Zhang, G., Liu, S., Chen, X., Peng, R., Dai, L., Qu, X., Li, S., Song, H., Gao, Z., Yuan, P., Liu, Z., Li, C., Shang, Z., Li, Y., Zhang, M., Qi, J., Wang, H., Du, N., Wu, Y., Bi, Y., Gao, S., Shi, Y., Yan, J., Zhang, Y., Xie*, Z., Wei*, W. and Gao*, G. F., 2019, Human neonatal Fc receptor is the cellular uncoating receptor for Enterovirus B. Cell, 177 (6): 1553-1565.
21. Wang, H., Shi, Y., Song, J., Qi, J., Lu, G., Yan, J., Gao*, G. F., 2016, Ebola Viral Glycoprotein Bound to Its Endosomal Receptor Niemann-Pick C1. Cell, 164 (1-2): 258-268.
22. Ma, W., Li, S., Ma, S., Jia, L., Zhang, F., Zhang, Y., Zhang, J., Wong, G., Zhang, S., Lu, X., Zhang, H., Yan, J., Li, W., Qin, C., Han, D., Qin, C., Wang, N., Li*, X. and Gao*, G. F., 2016, Zika virus causes testis damage and leads to male infertility in mice, Cell, 167 (6): 1511-1524.
23. Tong, Y.-G., Shi, W.-F., Liu, D., Bo, X.-C., Liang, L., Qian, J., Liu, J., Ren, H.-G., Fan, H., Ni, M., Sun, Y., Jin, Y., Teng, Y., Li, Z., Kargbo, D., Dafae, F., Kanu, A., Chen, C.-C., Lan, Z.-H., Jiang, H., Luo, Y., Lu, H.-J., Zhang, X.-G., Yang, F., Hu, Y., Cao, Y.-X., Deng, Y.-Q., Su, H.-X., Sun, Y., Liu, W.-S., Wang, Z., Wang, C.-Y., Bu, Z.-Y., Guo, Z.-D., Zhang, L.-B., Nie, W.-M., Bai, C.-Q., Sun, C.-H., An, X.-P., Xu, P.-S., Zhang, X.-L.-L., Huang, Y., Mi, Z.-Q., Yu, D., Yao, H.-W., Feng, Y., Xia, Z.-P., Zheng, X.-X., Yang, S.-T., Lu, B., Jiang, J.-F., Kargbo, B., He*, F.-C., Gao*, G. F., Cao*, W.-C. and The China Mobile Laboratory Testing Team in Sierra Leone, 2015, Genetic diversity and evolutionary dynamics of Ebola virus in Sierra Leone. Nature, 524 (7563): 93-96.
24. Shi, Y., Zhang, W., Wang, F., Qi, J., Wu, Y., Song, H., Gao, F., Bi, Y., Zhang, Y., Fan, Z., Qin, C., Sun, H., Liu, J., Haywood, J., Liu, W., Gong, W., Wang, D., Shu, Y., Wang, Y., Yan, J., Gao*, G. F., 2013, Structures and receptor binding of hemagglutinins from human-infecting H7N9 influenza viruses. Science, 342 (6155): 243-247.
25. Lu, G., Hu, Y., Wang, Q., Qi, J., Gao, F., Li, Y., Zhang, Y., Zhang, W., Yuan, Y., Bao, J., Zhang, B., Shi, Y., Yan, J. and Gao*, G. F., 2013, Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature, 500 (7461): 227-231.
26. Zhang, W., Shi, Y., Lu, X., Shu, Y., Qi, J., Gao*, G. F., 2013, An airborne transmissible avian influenza H5 hemagglutinin seen at the atomic level. Science, 340 (6139): 1463-1467.
27. Liu, D., Shi, W., Shi, Y., Wang D., Xiao, H., Li, W., Bi, Y., Wu, Y., Li, X., Yan, J., Liu, W., Zhao, G., Yang, W., Wang, Y., Ma, J., Shu*, Y., Lei*, F. and Gao*, G. F., 2013, Origin and diversity of novel avian influenza A H7N9 viruses causing human infections: phylogenetic, structural, and coalescent analyses. The Lancet, 381 (9881): 1926-1932.
28. Liu*, J., Xiao, H., Lei, F., Zhu, Q., Qin, K., Zhang, X. W., Zhang, X. L., Zhao, D., Wang, G., Feng, Y., Ma, J., Liu, W., Wang, J. and Gao*, G. F., 2005, Highly pathogenic H5N1 influenza virus infection in migratory birds. Science, 309 (5738): 1206.
29. Meng, S. D., Gao, T., Gao, G. F. and Tien*, P., 2001, HBV-specific peptide associated with heat-shock protein gp96. The Lancet, 357 (9255): 528-529.
30. Gao, G. F., Tormo, J., Gerth, U. C., Wyer, J. R., McMichael, A. J., Stuart, D. I., Bell, J. I., Jones, E. Y. and Jakobsen, B. K., 1997, Crystal structure of the complex between human CD8αα and HLA-A2. Nature, 387 (6633): 630-634. (With a front cover illustration (Cover story) and a short title in the front cover page: CD8 comes to grips with MHC).

中文文章 (Publications in Chinese)

1. 高福, 2016, 踏上新征程, 奔向新辉煌. 科学通报, 61 (1): 1. 
2. 王寒, 齐建勋, 刘宁宁, 李燕, 高俊, 张廷虹, 柴彦, 高峰, 张浩, 李向东, 叶昕, 严景华, 逯光文, 高福, 2015, 埃博拉病毒入侵:人TIM分子的结构与结合PS的分子基础. 科学通报, 60 (35): 3438-3453. (封面文章) 
3. 高福，2014, 打赢埃博拉“比赛”的下半场. 科学通报，59 (36): 3570-3571. 
4. 赖圣杰，Miniota, J., 王丽萍，任翔，张洪龙，李中杰，高福，Khan, K., 余宏杰*，2014，西非埃博拉病毒病传入中国的可能航线和风险估计. 科学通报，59 (36): 3572-3580. 
5. 李昱，任翔，刘翟，程颖，高福，余宏杰*，2014，埃博拉病毒病：流行病学、生态学、诊断、治疗与控制. 科技导报, 32 (24): 15-24. (封面文章)  
6. 程颖，刘军, 李昱, 刘翟, 任翔, 施一, 高福, 余宏杰*，2014，埃博拉病毒病：病原学、致病机制、治疗与疫苗研究进展. 科学通报，59: 2889-2899. 
7. 闫章才, 薛丽香, 李国才, 高福*, 董尔丹*, 2014, 流行性感冒防控基础研究状况及关键科学问题分析. 中国科学：生命科学， 44（1）：101-106. 
8. 逯光文，高福*，严景华*, 2013, 麻疹病毒受体与病毒侵入. 生物工程学报，29 (1): 1−9. (特邀综述) （封面文章） 
9. 刘军, 齐建勋, 高峰, 严景华, 高福*, 2011, T细胞功能学与结构免疫学结合方法鉴定 HLA－A2限制性的细胞毒性T淋巴细胞表位富集区. 科技导报, 29 (27): 19-26. (封面文章) 
10. 孙明伟, 路希山, 高福*, 2011, 合成病毒：对流感病毒研究的贡献. 生命科学, 23 (9): 921-930. 
11. 胡旭东, 路浩, 刘培培, 遇秀玲, 李爽, 王勇月, 莫毅诚, 张国中, 田克恭, 高福, 苏敬良*, 2011, 我国发现的一种引起鸭产蛋下降综合征的新型黄病毒. 中国兽医杂志, 47 (7): 43-47. 
12. 孙明伟, 高福*, 2011, 小议2010国内外生命科学重要进展. 遗传, 33 (2): 97-99.  
13. 李青, 冯恩光, 柳红, 高福*, 2010, 基于结构的抗流感病毒神经氨酸酶抑制剂的设计和研发.生物产业技术, (6): 42-48.  
14. 孙明伟, 郑焙文, 高福, 朱宝利*, 2010, 人类与病原菌的军备竞赛：NDM-1耐药基因与超级细菌. 生物工程学报, 26 (11): 1461-1472. (《新华文摘》2011年第1期转载) 
15. 孙明伟, 李寅, 高福*, 2010, 从人类基因组到人造生命：克雷格文特尔领路生命科学. 生物工程学报, 25 (6): 697-706. (《新华文摘》2010年第17期转载) 
16. 孙业平，高福*, 2010, 天然免疫抗病毒效应分子Mx 蛋白的结构与功能研究进展. 生物化学与生物物理进展, 37 (7): 699-706. (综述)  
17. 宋晓晖, 胡旭东, 马素芳, 王明旸, 张蔚, 马颖, 陈越, 马广鹏, 汪明, 杨希才, 刘文军 , 刘金华, 田波, 刘翟, 严景华, 高福*, 2009, 动物源性流感病毒与人流感流行. 科技导报, 27 (9): 19-24. (封面论文，《新华文摘》2009年第14期转载) 
18. 戴连攀, 周斌, 齐建勋, 马颖, 高福*, 杨希才*, 2009, 恒河猴MHC-I类分子Mamu-A*02与SIV抗原表位复合物的纯化和晶体学研究. 生物工程学报, 25 (7): 1028-1034. 
19. 张建华, 高峰, 彭浩, 夏春*, 高福*, 2009, 鸡β2-微球蛋白及其硒代衍生物的制备和晶体学研究. 科技导报, 27 (1): 38-41. 
20. 尹捷, 刘一苇, 李洁, 马延和, 向华, 严景华, 高福*, 2008, 腾冲嗜热厌氧杆菌6-磷酸-β-葡萄糖苷酶的表达与结晶及其功能鉴定. 中国生物化学与分子生物学报, 24 (10): 916-924. 
21. 校海霞, 严景华, 王贵华, 刘翟, 孙业平, 高福*, 2007, 禽流感研究进展：迁徙鸟的作用与反向遗传技术的贡献. 前沿科学, 1: 62-73. (综述) 
22. 王晓佳, 张卫红, 汪明*, 高福*, 2004, 囊膜病毒膜融合的分子机制. 生物化学与生物物理进展, 31 (6): 482-491. (综述) 

Book Chapters

1. Edited by Paul F. Torrence, Combating the Threat of Avian Influenza: Drug Discovery Approaches, John Wiley & Sons Inc., 2007, USA, ISBN 987-0-470-11879-5. Chapter 10: Peptide Inhibitors Targeting Virus-Cell Fusion in Class I Enveloped Viruses, George Fu Gao. 
2. Major Histocompatibility Complex: Interaction with Peptides, In: eLS. John Wiley & Sons, Ltd, 2011, Chichester. DOI: 10.1002/9780470015902.a0000922.pub2. Jun Liu, George Fu Gao. 
3. Edited by Pier Andrea Serra, Biosensors for Health, Environment and Biosecurity, InTech, 2011, Croatia, ISBN 978-953-307-443-6. Chapter 7: Label-free Biosensors for Health Applications, Cai Qi, George Fu Gao and Gang Jin. 
4. Edited by Shuiping Jiang, Regulatory T Cells and Clinical Application, Springer, 2008, New York, ISBN 978-0-387-77908-9. Chapter 21: Regulatory T Cells in Hepatitis and Hepatocellular Carcinoma, Fu-Sheng Wang and George Fu Gao. 
5. Edited by Qinghua Wang, Influenza: Current Research, Horizon Scientific Press and Caister Academic Press, 2015, USA. Avian Influenza H7N9 Virus, Ying Wu, Yi Shi, Jun Liu, Yan Wu and George F Gao. 

中文书籍 (Book chapters in Chinese)

1. 曹雪涛主编 , 免疫学前沿进展( 第一版), 人民卫生出版社 , 2009, ISBN 987-7-117-12311-2. 第六章: 结构免疫学研究进展: 主要组织相容性复合物的分子识别, 施一, 刘军, 高福。 
   曹雪涛主编 , 免疫学前沿进展 (第二版), 人民卫生出版社 , 2011, ISBN 978-7-117-14763-7. 第七章: 结构免疫学研究进展: 主要组织相容性复合物的分子识别, 施一, 刘军, 高福。 
2. U. 克拉格 (U. Kragl) [德]主编, 曹竹安 主译, 高福 主校, 生物技术产业化—从实验室到工厂到产品, 应用生物技术大系, 科学出版社, 2008, ISBN 978-7-03-021732-5。 
3. 谢克特 (M. Schaechter) 编, 高福, 黄力, 谭华荣 主编译, 微生物学案头百科 (The Desk Encyclopedia of Microbiology), 英文原版名作中文导读系列, 科学出版社, 2006, ISBN 7-03-016711-2。 
4. A. D. 莱曼 (A. D. Leman) 主编, 刘文军, 张仲秋, 狄伯雄, 陈德威, 唐桂运, 高福, 龚人雄等 主译校, 猪病学 (第六版)，北京农业大学出版社, 1990, 北京。 
5. B. W. 卡尔尼科 (B. W. Calnek) 主编, 高福, 刘文军 主译, 郭玉璞, 狄伯雄 主校, 禽病学 (第九版), 北京农业大学出版社, 1991.11, 北京。
   第 10 和 11 版的翻译： 
   B. W. 卡尔尼科 (B. W. Calnek) 主编, 高福, 苏敬良主译, 郭玉璞, 狄伯雄 主校, 禽病学 (第十版), 中国农业出版社，1999.10，北京。 
   Y. M. 塞弗 (Y. M. Saif) 主编, 苏敬良, 高福, 索勋主译, 郭玉璞 主校, 禽病学 (第十一版) (世界兽医经典著作译丛), 中国农业出版社, 2005.1, ISBN 7-109-09486-3, 北京。 
6. 郭德银，高福 编，病毒学家----田波院士，武汉大学出版社，2011，武汉。 
7. 彼得•杜赫提 (Peter Doherty) 著, 马颖, 孙业平译，高福, 徐小宁审校，通往诺贝尔奖之路，科学出版社，2013，北京。 
8. 余宏杰 主编，高福 主审，埃博拉出血热公众防护问答，科学普及出版社，2014，北京。 
9. 余宏杰 主编，高福 主审，中东呼吸综合征公众防护问答，科学普及出版社，2015，北京。 
10. 余宏杰 主编，高福 主审，寨卡病毒病公众防护问答，科学普及出版社，2016，北京。